NAV3 and Alzheimer disease: In Kaplan-Meier analyses, we further stratified subjects into low and high MCP-1 group, and significantly lower AD-free probability was observed among subjects having high blood MCP-1 (75% percentile as cutoffs) and among subjects with NAV3 rs696468-CC carriers (p = 3.6×10− 5, Fig. 3C) and subjects with UNC5C rs72659964-AT + TT carriers (p = 6.1×10− 4, Fig. 3D) (50% percentile as cutoffs in Figure S2).